Trial Profile
A Phase II Study of Short-course Radiotherapy Preoperatively followed by Capecitabine and Oxaliplatin (XELOX) for cT3 Node-positive Lower Rectal Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Aug 2020
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Oxaliplatin (Primary) ; Bevacizumab
- Indications Adenocarcinoma; Rectal cancer
- Focus Therapeutic Use
- Acronyms ADVANCE-RC study
- 31 Jul 2020 Status changed from recruiting to completed.
- 02 Aug 2016 New trial record